Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/56705 |
Resumo: | Ministério da Ciência, Tecnologia e Inovação - Brasil. Conselho Nacional de Pesquisa (CNPq). |
| id |
CRUZ_fa5ede9b2d2ec9988d231c587c2dc9b0 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/56705 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Cincura, CarolinaCosta, Rubia S.Lima, Clara Monica F. deOliveira Filho, JamaryRocha, Paulo NovisCarvalho, Edgar M.Lessa, Marcus M.2023-01-27T17:03:26Z2023-01-27T17:03:26Z2022CINCURA, Carolina et al. Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline. Tropical Medicine and Infectious Disease, v. 7, p. 1-9, 2022.2414-6366https://www.arca.fiocruz.br/handle/icict/5670510.3390/tropicalmed7110383Ministério da Ciência, Tecnologia e Inovação - Brasil. Conselho Nacional de Pesquisa (CNPq).Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Otorrinolaringologia. Unidade Cérvico-Facial. Salvador, BA, Brasil.Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil.Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Otorrinolaringologia. Unidade Cérvico-Facial. Salvador, BA, Brasil.Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais. Salvador, BA, Brasil.Universidade Federal da Bahia. Faculdade de Medicina da Bahia. Departamento de Medicina Interna e Apoio Diagnóstico. Salvador, BA, Brasil.Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Instituto Nacional de Ciência e Tecnologia de Doenças Tropicais. Salvador, BA, Brasil.Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Imunologia. Salvador, BA, Brasil / Universidade Federal da Bahia. Complexo Hospitalar Universitário Professor Edgard Santos. Serviço de Otorrinolaringologia. Unidade Cérvico-Facial. Salvador, BA, Brasil / Universidade Federal da Bahia. Faculdade de Medicina da Bahia. Departamento de Cirurgia Experimental e Especialidades Cirúrgicas. Salvador, BA, Brasil.Mucosal leishmaniasis (ML) is a severe form of tegumentary leishmaniasis associated with a persistent inflammatory response. High levels of TNF, IFN-γ, CXCL9 and CXCL10 are found in ML patients, and the association of pentoxifylline with antimony is more effective in decreasing the healing time in ML patients when compared to antimony alone. The present study aimed to investigate the existence of a correlation between cytokine and chemokine production and ML severity and evaluate the potential value of cytokine and chemokine production as marker of therapeutic response in ML patients. This prospective study included 86 subjects in an area of endemic Leishmania braziliensis transmission. Patients diagnosed with ML were classified into clinical stages ranging from I to V according to disease severity. TNF, IFN-γ, CXCL9 and CXCL10 levels were quantified in the supernatant of the mononuclear cell cultures by ELISA before and after treatment with antimony alone or antimony plus pentoxifylline. The median TNF level in the group with mild disease (Stages I–II) was 1064 pg/mL (142–3738 pg/mL), while, in the group with moderate or severe disease (Stages III–V), it was 1941 pg/mL (529–5294 pg/mL) (p = 0.008). A direct correlation was observed between ML clinical severity and levels of TNF production (r = 0.44, p = 0.007). Patients who were treated with antimony and pentoxifylline healed significantly faster than those treated with antimony alone (52 vs. 77 days, hazard ratio = 0.60; 95% confidence interval = 0.38–0.95, p = 0.013). Therapeutic failure was higher in the group that received antimony alone (25% vs. 7%; p = 0.041). There was a significant decrease in CXCL9 after therapy of ML in both groups (p = 0.013; p = 0.043). TNF levels are associated with the severity of mucosal diseases, and pentoxifylline associated with antimony should be the recommended therapy for ML in countries where liposomal amphotericin B is not available.engMDPIQuimiocina CXCL9Quimiocina CXCL10TNFIFN-γEstágio da doençaGravidadeMucosa leishmaniosePentoxifilinaAntimônioChemokine CXCL9Chemokine CXCL10TNFIFN-γDisease stageSeverityMucosal leishmaniasisPentoxifyllineAntimonyQuimiocina CXCL9Quimiocina CXCL10PentoxifilinaAntimônioAssessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifyllineinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/56705/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALCincura,C. Assessment of Immune.pdfCincura,C. Assessment of Immune.pdfapplication/pdf693014https://www.arca.fiocruz.br/bitstream/icict/56705/2/Cincura%2cC.%20Assessment%20of%20Immune.pdf5c2e600c28d9082a1a34128126f6b4caMD52icict/567052023-03-15 14:32:50.882oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:32:50Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.en_US.fl_str_mv |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| title |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| spellingShingle |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline Cincura, Carolina Quimiocina CXCL9 Quimiocina CXCL10 TNF IFN-γ Estágio da doença Gravidade Mucosa leishmaniose Pentoxifilina Antimônio Chemokine CXCL9 Chemokine CXCL10 TNF IFN-γ Disease stage Severity Mucosal leishmaniasis Pentoxifylline Antimony Quimiocina CXCL9 Quimiocina CXCL10 Pentoxifilina Antimônio |
| title_short |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| title_full |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| title_fullStr |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| title_full_unstemmed |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| title_sort |
Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline |
| author |
Cincura, Carolina |
| author_facet |
Cincura, Carolina Costa, Rubia S. Lima, Clara Monica F. de Oliveira Filho, Jamary Rocha, Paulo Novis Carvalho, Edgar M. Lessa, Marcus M. |
| author_role |
author |
| author2 |
Costa, Rubia S. Lima, Clara Monica F. de Oliveira Filho, Jamary Rocha, Paulo Novis Carvalho, Edgar M. Lessa, Marcus M. |
| author2_role |
author author author author author author |
| dc.contributor.author.fl_str_mv |
Cincura, Carolina Costa, Rubia S. Lima, Clara Monica F. de Oliveira Filho, Jamary Rocha, Paulo Novis Carvalho, Edgar M. Lessa, Marcus M. |
| dc.subject.other.en_US.fl_str_mv |
Quimiocina CXCL9 Quimiocina CXCL10 TNF IFN-γ Estágio da doença Gravidade Mucosa leishmaniose Pentoxifilina Antimônio |
| topic |
Quimiocina CXCL9 Quimiocina CXCL10 TNF IFN-γ Estágio da doença Gravidade Mucosa leishmaniose Pentoxifilina Antimônio Chemokine CXCL9 Chemokine CXCL10 TNF IFN-γ Disease stage Severity Mucosal leishmaniasis Pentoxifylline Antimony Quimiocina CXCL9 Quimiocina CXCL10 Pentoxifilina Antimônio |
| dc.subject.en.en_US.fl_str_mv |
Chemokine CXCL9 Chemokine CXCL10 TNF IFN-γ Disease stage Severity Mucosal leishmaniasis Pentoxifylline Antimony |
| dc.subject.decs.en_US.fl_str_mv |
Quimiocina CXCL9 Quimiocina CXCL10 Pentoxifilina Antimônio |
| description |
Ministério da Ciência, Tecnologia e Inovação - Brasil. Conselho Nacional de Pesquisa (CNPq). |
| publishDate |
2022 |
| dc.date.issued.fl_str_mv |
2022 |
| dc.date.accessioned.fl_str_mv |
2023-01-27T17:03:26Z |
| dc.date.available.fl_str_mv |
2023-01-27T17:03:26Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
CINCURA, Carolina et al. Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline. Tropical Medicine and Infectious Disease, v. 7, p. 1-9, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/56705 |
| dc.identifier.issn.en_US.fl_str_mv |
2414-6366 |
| dc.identifier.doi.none.fl_str_mv |
10.3390/tropicalmed7110383 |
| identifier_str_mv |
CINCURA, Carolina et al. Assessment of immune and clinical response in patients with mucosal leishmaniasis treated with pentavalent antimony and pentoxifylline. Tropical Medicine and Infectious Disease, v. 7, p. 1-9, 2022. 2414-6366 10.3390/tropicalmed7110383 |
| url |
https://www.arca.fiocruz.br/handle/icict/56705 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/56705/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/56705/2/Cincura%2cC.%20Assessment%20of%20Immune.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 5c2e600c28d9082a1a34128126f6b4ca |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798324833851801600 |